LAG3 and urothelial carcinoma: The targeting of LAG-3 in combination with other checkpoint therapies has been a focus of ongoing clinical trials – exemplified by a recent study that associated LAG-3 expression on peripheral CD8+ T cells with a poorer efficacy of checkpoint blockade in melanoma and urothelial carcinoma patients [22].